Get regular updates to your inbox.
Firazyr (icatibant injection) appears to be at least as safe and effective at controlling swelling attacks in hereditary angiodema (HAE) patients with normal C1 inhibitor (C1-INH) activity as among those with reduced or no C1-INH activity, according to real-world data from Brazilian patients. Most attacks were successfully treated with…
A woman developed symptoms of angioedema after taking enalapril, a medicine commonly used to lower blood pressure and treat heart problems, according to a report from Colombia. Her symptoms of heart failure resolved a few days after she stopped taking the medication. This is a known side effect of…
Sebetralstat, KalVista Pharmaceuticals‘ investigational on-demand treatment for swelling attacks in people with hereditary angioedema (HAE), led to a rapid and sustained suppression of kallikrein in HAE patients, according to data from a Phase 2 trial. As previously reported, the use of sebetralstat also was associated with fast…
Regulatory health agencies in Canada and Switzerland have approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) as the first daily oral therapy to prevent hereditary angioedema (HAE) attacks. With these approvals, Orladeyo will be available in the two countries for the routine prevention of HAE attacks in patients ages 12 and…
An “airway watch” via nasopharyngolaryngoscopy (NPL) may help triage patients with angioedema who will need breathing support in the intensive care unit (ICU), a study found. NPL is a procedure in which a narrow tube with a camera on its end is passed through the nose to allow doctors…
Death due to breathing difficulties associated with hereditary angioedema (HAE) remains a concern in Brazil, highlighting that misdiagnosis and a lack of treatment access in lower-income countries may contribute to increased mortality rates, a recent study highlights. While HAE-associated deaths have declined significantly in recent years within high-income countries,…
The first case of a patient developing angioedema accompanied by hives after treatment with solifenacin, a medication commonly used to treat urinary incontinence, was described in a recent case report. The report, “Solifenacin-induced acute urticaria and angioedema: a rare adverse effect,” was published in the Postgraduate Medical…
Long-term preventive (prophylactic) treatment with Haegarda is safe, decreases how often swelling attacks occur in patients with hereditary angioedema (HAE), and how often they rely on rescue medications to treat swelling attacks. These findings come from an open-label extension study (NCT02316353) of the Phase 3 COMPACT trial…
KVD900, KalVista Pharmaceuticals’ investigational on-demand treatment for swelling attacks in people with hereditary angioedema (HAE), will now be called sebetralstat, the company announced. Sebetralstat will become the nonproprietary nomenclature for the treatment’s active ingredients, meaning that will be the generic name for any medication using the same formulation…
A new hereditary angioedema (HAE) registry, touted as the first of its kind, is using real-world data to provide comprehensive insights into patients’ journeys. The Trio-CIIC HAE Registry derives from a partnership between real-world data provider Trio Health and the Consortium of Independent Immunology Clinics (CIIC), a professional organization…
Get regular updates to your inbox.